<DOC>
	<DOCNO>NCT00510471</DOCNO>
	<brief_summary>The treatment investigate patient- tumor-specific therapy know personalized active immunotherapy . Personalized active immunotherapy attempt use person 's immune system combat disease . Sargramostim ( a.k.a . GM-CSF ) give together personalize active immunotherapy may increase immune system 's response , therefore , aid effect personalize active immunotherapy . This approach previously study patient follicular Non-Hodgkin 's lymphoma B-cell malignancy . Encouraging efficacy result favorable safety profile see date study .</brief_summary>
	<brief_title>Personalized Active Immunotherapy ( Vaccine Therapy ) Sargramostim Given After Standard Care Treatment With Rituximab Chemotherapy Initial Treatment With Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>1 . Written inform consent 2 . Previously untreated follicular NHL 3 . Stage III IV disease require treatment 4 . Able receive rituximab chemotherapy ( rituximab cyclophosphamide , vincristine , prednisone either without doxorubicin ) 5 . Able provide tumor sample adequate IdKLH manufacture 6 . ≥ 18 year age 7 . At least one bidimensionally measurable lesion ≥ 2 cm CT scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>